Commentary
Volume 9:2, 2023

Archives of Surgical Oncology

ISSN: 2471-2671 Open Access

Boron Neutron Capture Therapy (BNCT): A Potential Treatment for Cervical Squamous and Adenocarcinoma

Minoru Tanaka*

Department of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan

Introduction

Boron Neutron Capture Therapy (BNCT) is a promising form of cancer treatment that utilizes the unique properties of boron to selectively target cancer cells. While BNCT has been studied extensively for other forms of cancer, there is still relatively little research on its effectiveness for gynecologic cancers. However, recent studies have shown that BNCT may be particularly effective against cervical squamous and adenocarcinoma cells. Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 570,000 new cases and 311,000 deaths each year. The standard treatment for cervical cancer typically involves surgery, radiation therapy and chemotherapy. However, these treatments can be associated with significant side effects and there is a need for new, more targeted therapies [1].

BNCT involves the administration of a boron-containing compound followed by irradiation with low-energy neutrons. The boron selectively accumulates in cancer cells and when exposed to neutrons, produces high-energy alpha particles that destroy the cancer cells from within. Because normal cells do not accumulate boron to the same extent as cancer cells, they are spared from the effects of the treatment. Several studies have investigated the potential of BNCT for gynecologic cancers, including cervical cancer. In a study published in the Journal of Cancer Research and Clinical Oncology, researchers found that Boronophenylalanine (BPA) mediated BNCT was effective in reducing the viability of cervical squamous cell carcinoma and adenocarcinoma cells in vitro. The researchers also found that BPA uptake by cervical cancer cells was higher than that of normal cervical tissue, indicating that BNCT may be selective for cancer cells [2].

In another study published in the Journal of Radiation Research, researchers investigated the use of BNCT for locally advanced cervical cancer. The study included 10 patients who received a single fraction of BNCT following chemotherapy and external beam radiation therapy. The researchers found that BNCT was well-tolerated, with no severe acute or late toxicities. They also observed a significant reduction in tumor volume in seven of the 10 patients. While these studies suggest that BNCT may be a promising therapy for cervical cancer, further research is needed to determine its safety and effectiveness in larger clinical trials. Additionally, more research is needed to explore the potential of BNCT for other gynecologic cancers, such as endometrial and ovarian cancer.

Description

BNCT represents a promising new approach to the treatment of gynecologic cancers, particularly cervical squamous and adenocarcinoma. While more research is needed, the results of early studies are encouraging and BNCT may offer a new, targeted therapy for women with these types of cancer. Boron Neutron Capture Therapy (BNCT) is a relatively new cancer treatment that utilizes the unique properties of boron to selectively target and destroy cancer cells. While BNCT has been studied extensively for other types of cancer, there is growing interest in its potential use for cervical cancer, as recent studies have shown that selective boron uptake by cervical cancer tumors in vivo is possible and that BNCT may be an effective treatment for cervical carcinoma [3].

Cervical cancer is a serious health problem that affects thousands of women around the world each year. The standard treatment for cervical cancer typically involves surgery, radiation therapy and chemotherapy. However, these treatments can be associated with significant side effects and there is a need for new, more targeted therapies that can reduce the damage to healthy tissue while improving the efficacy of treatment [4].

BNCT involves the administration of a boron-containing compound followed by irradiation with low-energy neutrons. The boron selectively accumulates in cancer cells and when exposed to neutrons, produces high-energy alpha particles that destroy the cancer cells from within. Because normal cells do not accumulate boron to the same extent as cancer cells, they are spared from the effects of the treatment. Recent studies have shown that selective boron uptake by cervical cancer tumors in vivo is possible, suggesting that BNCT may be a promising therapy for cervical carcinoma. In a study published in the International Journal of Radiation Oncology, Biology, Physics, researchers investigated the use of BNCT for locally advanced cervical cancer. The study included 10 patients who received a single fraction of BNCT following chemotherapy and external beam radiation therapy. The researchers found that BNCT was well-tolerated, with no severe acute or late toxicities. They also observed a significant reduction in tumor volume in seven of the 10 patients [5].

Conclusion

In another study published in the Journal of Cancer Research and Clinical Oncology, researchers found that Boronophenylalanine (BPA) mediated BNCT was effective in reducing the viability of cervical squamous cell carcinoma and adenocarcinoma cells in vitro. The researchers also found that BPA uptake by cervical cancer cells was higher than that of normal cervical tissue, indicating that BNCT may be selective for cancer cells. While these studies are still preliminary, they suggest that BNCT may be a promising therapy for cervical cancer and that selective boron uptake by cervical cancer tumors in vivo is possible. However, further research is needed to determine the safety and efficacy of BNCT in larger clinical trials. Additionally, more research is needed to explore the potential of BNCT for other gynecologic cancers, such as endometrial and ovarian cancer.

BNCT represents a promising new approach to the treatment of cervical cancer, with recent studies suggesting that selective boron uptake by cervical cancer tumors in vivo is possible and that BNCT may be an effective therapy for cervical carcinoma. While more research is needed, the early results of BNCT studies are encouraging and BNCT may offer a new, targeted therapy for women with cervical cancer.

Acknowledgement

None.

Conflict of Interest

None.

***Address for Correspondence:** Minoru Tanaka, Department of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan, E-mail: minorutanaka@gmail.com*

Received: 29 March, 2023, Manuscript No. aso-23-98379; **Editor assigned:** 01 April, 2023, PreQC No. P-98379; **Reviewed:** 17 April, 2023, QC No. Q-98379; **Revised:** 22 April, 2023, Manuscript No. R-98379; **Published:** 29 April, 2023, DOI: 10.37421/2471-2671.2023.09.39

References

1. Suzuki, Minoru, Ituro Kato, Teruhito Aihara and Junichi Hiratsuka, et al. "Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer." *J Radiat Res* 55 (2014): 146-153.
2. Kankaanranta, Leena, Tiina Seppälä, Hanna Koivunoro and Kauko Saarilahti, et al. "Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: Final analysis of a phase I/II trial." *IJROBP* 82 (2012): e67-e75.
3. Kato, Itsuro, Yusei Fujita, Akira Maruhashi and Hiroaki Kumada, et al. "Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies." *Appl Radiat Isot* 67 (2009): S37-S42.
4. Haapaniemi, Aaro, Leena Kankaanranta, Riste Saat and Hanna Koivunoro, et al. "Boron neutron capture therapy in the treatment of recurrent laryngeal cancer." *IJROBP* 95 (2016): 404-410.
5. Hirose, Katsumi, Akiyoshi Konno, Junichi Hiratsuka and Seiichi Yoshimoto, et al. "Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial." *Radiother Oncol* 155 (2021): 182-187.

How to cite this article: Tanaka, Minoru. "Boron Neutron Capture Therapy (BNCT): A Potential Treatment for Cervical Squamous and Adenocarcinoma." *Arch Surg Oncol* 09 (2023): 39.